// App-Quantinova.ai

2520 : POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.

Researchers

Presenter

  • Richard D. Baird

Principal Investigators

  • Mafalda Oliveira

  • Karin Beelen

  • Javier Garcia-Corbacho

  • Ingrid A M Mandjes

  • Anne-Laure Vallier

  • Erik D. van Werkhoven

  • Sanjeev Srinivas Kumar

  • Harm van Tinteren

  • Emma Beddowes

  • Hilde Rosing

  • Mariette Schrier

  • Aurelia de Vries Schultink

  • Cristina Saura

  • Rene Bernards

  • Josep Tabernero

  • Javier Cortes

  • Carlos Caldas

  • Sabine C. Linn

Medical Centers

  • Cambridge Cancer Centre, Cambridge, United Kingdom

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

Locations

  • Spain

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Human epidermal growth factor receptor 2

  • Circulating DNA

Drug/Treatment

  • Tamoxifen

  • Taselisib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • I

Study Id's

  • NCT02285179

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved